(MedPage Today) — With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) — and more waiting in the wings — choosing one has become a new challenge, with softer endpoints expected to gain prominence…
Source link : https://www.medpagetoday.com/spotlight/attr-cm/117736
Author :
Publish date : 2025-10-01 16:22:00
Copyright for syndicated content belongs to the linked Source.
